Abbott (NYSE: ABT), which describes itself as the global healthcare leader, said on October 21, 2026 that it intends to separate its global Nutrition business into an independent, publicly traded company. The mechanism to effect this transaction is a tax-free distribution of shares in the new company to Abbott’s shareholders, structured to qualify as a tax-free separation for U.S. federal income tax purposes. Abbott shareholders would end up owning shares in both Abbott and the independent Nutrition company, with completion expected by the end of 2027.

The Nutrition company includes approximately $8.5Bn in annual sales, about 16,000 employees and 14 manufacturing sites. The remaining Abbott would include sales of approximately $42.0Bn and about 106,000 employees. The announcement was made on the same morning as third-quarter results, likely to present the strategic reset and the quarter together.

Mechanics and Sequencing

Completion remains subject to customary conditions, including regulatory approvals, the effectiveness of a registration statement on Form 10 and final approval by the Abbott Board of Directors. The forward-looking statements section separately flags applicable regulatory approvals and tax rulings as factors, a usual signal that the tax-free treatment is not yet settled definitively. Daniel Salvadori, executive vice president and group president, Established Pharmaceuticals and Nutritional Products, is designated to become Chief Executive Officer of the new company, and Abbott has not disclosed a name or a headquarters for that entity. The Nutrition business will continue to operate as part of Abbott throughout the separation process.

Two details likely matter to income-oriented holders. Abbott expects the combined dividend paid by the two companies to equal Abbott’s dividend at the time of separation, which removes a common source of anxiety around a distribution. The planned separation will also not affect Abbott’s 2026 guidance or the 2027 guidance the company plans to provide in January. One-time charges related to the transaction are expected in the periods preceding separation, though these have not yet been quantified.

The Case Abbott Is Making

Robert B. Ford, Abbott’s Chairman and Chief Executive Officer, framed the logic in terms of fit rather than failure, saying the separation will benefit both companies and set each one up for maximum success in its respective market. The release argues that different investment identities and requirements, growth profiles and innovation cycles leave both businesses better served by resource and capital allocation aligned to their distinct models. Abbott also states that the remaining company will have accelerated sales growth and an expanded margin profile, which is about as close as a release comes to conceding that Nutrition has been a drag on both measures.

The surrounding context is harder for Abbott to address directly, and the company has not framed it as the stated reason for the separation. Nutrition has absorbed a series of setbacks since the 2022 recall and shutdown of the Sturgis, Michigan plant, including the reported loss of a major U.S. government supply contract last year and higher manufacturing costs. Reported infant-formula litigation settlements include approximately $385.0MM agreed in September 2026 and approximately $670.0MM agreed in August 2026. On the earnings call, the chief executive reportedly ruled out a sale of the business and said outstanding legal disputes were unlikely to delay the separation, which suggests Abbott views the litigation as manageable rather than structural.

What Each Company Looks Like Afterwards

The independent Nutrition company would start with a portfolio that few competitors could assemble: Similac, PediaSure, Pedialyte, Glucerna and Ensure. Abbott describes Ensure, PediaSure and Glucerna as the world’s No. 1 brands in adult nutrition supplement drinks, pediatric nutrition supplements and diabetes management nutrition, respectively, with Similac the No. 1 infant formula brand in the U.S. As a standalone company, it would likely compete for capital on terms closer to consumer staples, where brand strength, pricing discipline and manufacturing reliability matter more than clinical innovation cycles. Abbott’s argument is that independence will allow resources to be focused more strategically across innovation, commercial activities and key initiatives. In practice, that probably means increased marketing spend and plant investment that would otherwise struggle for priority inside the larger medtech portfolio.

The remaining Abbott would be a roughly $42.0Bn business built around what Ford called core higher-growth, innovation-driven assets, with devices and diagnostics at the center. The release cites 10 product launches in the first half of 2026, a cadence that may support a higher multiple if it holds. Investors will probably test whether the margin expansion Abbott describes is arithmetic from removing a lower-margin unit or genuine operating improvement. Only the second would justify a lasting re-rating.

Sector Implications

Separations of this kind have become a well-established route for large healthcare and consumer groups over the past five years. The recent precedents include GSK’s separation of Haleon in 2022, Johnson & Johnson’s distribution of Kenvue in 2023, Novartis’s spin-off of Sandoz the same year and 3M’s listing of Solventum in 2024. Abbott itself separated AbbVie in 2013, which gives the board direct experience with the mechanics. The common thread is a parent retaining the higher-growth, innovation-led franchise and sending the slower-growth, brand-led business to its own shareholder base.

Post-separation performance across that cohort has been mixed. Several of the spun-off consumer businesses have traded below initial expectations, while parents have more often been rewarded for the cleaner equity story. If that pattern repeats, it would likely favor Abbott holders and leave the Nutrition company needing to prove that category leadership converts into returns without a larger balance sheet behind it.

What to Watch Through 2027

The practical milestones are the Form 10 filing, the tax rulings and the January 2027 guidance. The Form 10 should reveal capital structure and historical segment economics in detail, at which point investors can model the separation rather than simply assess its direction. The naming and headquarters decisions remain open, and the absence of a quote from the incoming chief executive in the release suggests the new company’s external positioning is still being assembled.

Shares were reported down about 4.0% on the day, though Abbott also trimmed its 2026 outlook that morning to sales growth of about 6.0% from a prior 6.5% to 7.5% range and tightened adjusted EPS to $5.50-$5.55 from $5.45-$5.60. Reported third-quarter results were roughly in line, with adjusted profit of $1.42 per share on revenue of $13.01Bn, so the guidance revision rather than the separation may account for much of the move. Abbott appears to have chosen clarity over consolidated scale, accepting a smaller revenue base in exchange for a portfolio that likely grows faster and carries a higher margin. Whether the separation also creates value for the Nutrition company depends on execution that will not be visible until well after 2027. Shareholders will hold both sides of that outcome, which is the defining feature of a distribution rather than a sale.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan’s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial